1. Researchers call out Gilead over diversity of remdesivir trials — Bristol-Myers commits $300M to combat racial disparities — Goldman predicts at least one coronavirus vaccine approval before the end of 2020 — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

gettin sued

Discussion in 'Savient' started by Anonymous, Jan 31, 2014 at 9:59 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    finally getting called on their BS about funding operations and working their strategy. would be really cool if they get taken to the cleaners. special place in hell for these execs
     

  2. Anonymous

    Anonymous Guest

    Don't forget to take Maggie
     
  3. Anonymous

    Anonymous Guest

    dream on
     
  4. Anonymous

    Anonymous Guest

    exactly. they are slippery enough and wrote such huge safe harbor satements ("everything that follows is likely BS and you should not believe anything we put out there") that nothing will happen. Will probably con other companies into hiring them as well, saying "it was the other execs - not me".
     
  5. Anonymous

    Anonymous Guest

    Can you get sued for being just plain stupid? That is what it boils down to.
     
  6. Anonymous

    Anonymous Guest

    Yes, stupid people can be sued by even stupider people. Getting sued does not mean they will prevail in court.....just that they have found a lawyer to take it on contingency.....or that they are dumb enough to pay a shyster.
     
  7. Anonymous

    Anonymous Guest

    The really stupid people are the ones who bought this product for the amount they paid. One can only wonder how the crealta team hopes to recoup the $120MM purchase price. There is a shortage of pentobarbital for lethal injection, perhaps they hope to substitute krystexxa?
     
  8. Anonymous

    Anonymous Guest

    Perhaps Crealta will more than recoup its investment by bringing a level of credibility and professionalism to the product, which you might neither understand nor appreciate. Good luck in your next career, whatever that may be (hopefully, not in biopharmaceuticals).
     
  9. Anonymous

    Anonymous Guest

    Yes I am sure you are right, that high level of professionalism will overcome the immunogenicity issues that are stated in the product insert:

    "Anti-pegloticase antibodies developed in 92% of patients treated with KRYSTEXXA every 2 weeks...... Anti-PEG antibodies were also detected in 42% of patients treated with KRYSTEXXA"

    A more professional sales team can spin that into a positive attribute for this product.
     
  10. Anonymous

    Anonymous Guest

    They don't have to sell much! Think about it...they paid CASH for SVNT. Yes, it was 120MM; way over priced. BUT, when you cut out all of the Executive pay and only have about 4-5MM in overhead, then they can recoupe their investment and then some.

    KRY will make about 6MM to 7MM a Q already and that's 24-28MM for 2014. Not bad considering all the numb nuts are gone (except Parul). For some reason they promoted his ass.
     
  11. Anonymous

    Anonymous Guest

    Good point. The top line might be as much as 20-25% of the purchase price. From the last 10Q sales were almost 7MM and the cost of goods (excluding SG&A) was 1.4MM. They might just make a go of it if they can contain expenses.